ArticleTherapeutic advances in psychopharmacology2026
Effects of cariprazine on cholesterol, glucose, and weight in patients with schizophrenia: a systematic review and meta-analysis.
Article in Therapeutic advances in psychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cariprazine is a second-generation antipsychotic approved for treating schizophrenia, acute manic or mixed episodes associated with bipolar I disorder, and major depressive disorder. Antipsychotic treatment is often associated with metabolic alterations, including weight gain, dyslipidemia, and increased risk of type 2 diabetes and cardiovascular disease. Objectives: We performed a systematic review and meta-analysis with the overarching aim of synthesizing study results that describe the effect of cariprazine on glucose and lipid homeostasis, as well as weight, in persons living with schizophrenia. Design: A systematic literature review and meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Data sources and methods: We systematically searched three major electronic databases of medical and social science research papers (PubMed/MEDLINE, PsycINFO, and Cochrane Central Register of Controlled Trials (CENTRAL) for relevant titles and abstracts published between January 2014 and March 2025. Results: Using the Covidence platform, we included 12 studies for the systematic review and four randomized controlled studies for the meta-analysis. Meta-analysis revealed a significant difference in weight change between cariprazine and placebo; however, no significant differences were observed for total cholesterol or fasting glucose. Conclusion: This meta-analysis suggests that cariprazine, although associated with modest weight gain, does not cause significant alterations in lipid and glycemic profiles, confirming its favorable metabolic profile compared to other atypical antipsychotics. Trial registration: This study is registered with the International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY), 2025100014.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.